Archive for the ‘CRISPR/Cas9 & Gene Editing’ Category

Dr. Doudna: RNA synthesis capabilities of Synthego’s team represent a significant leap forward for Synthetic Biology

Posted in Big Data, BioIT: BioInformatics, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, Computational Biology/Systems and Bioinformatics, CRISPR/Cas9 & Gene Editing, Genome Biology, HealthCare IT, Intelligent Information Systems, mRNA Therapeutics on January 4, 2017| Leave a Comment »

Dr. Doudna: RNA synthesis capabilities of Synthego’s team represent a significant leap forward for Synthetic Biology

Reporter: Aviva Lev-Ari, PhD, RN

Synthego Raises $41 Million From Investors, Including a Top Biochemist

By MICHAEL J. de la MERCED JAN. 4, 2017

Jennifer Doudna, a professor at the University of California, Berkeley who helped develop advanced gene-editing techniques, is among investors in Synthego.

Synthego also drew in Dr. Doudna, who had crossed paths with the company’s head of synthetic biology at various industry conferences. According to Mr. Dabrowski, the money from her trust represents the single-biggest check from a non-institutional investor that the start-up has raised.

Synthego’s new funds will help the company take its products to a more global customer base, as well as broaden its offerings. The longer-term goal, Mr. Dabrowski said, is to help fully automate biotech research and take care of much of the laboratory work that scientists currently handle themselves.

The model is cloud technology, where companies rent out powerful remote server farms to handle their computing needs rather than rely on their own hardware.

“We’ll be able to do their full research workflow,” he said. “If you look at how cloud computing developed, it used to be that every company handled their server farm. Now it’s all handled in the cloud.”

SOURCE

Dr. Jennifer Doudna (UC Berkeley): PMWC 2017 Luminary Award, January 22, 2017 @PMWC 2017, January 23-25, Silicon Valley

Posted in CRISPR/Cas9 & Gene Editing, Interviews with Scientific Leaders, Personalized and Precision Medicine & Genomic Research on December 20, 2016| Leave a Comment »

WordCloud Image Produced by Adam Tubman

Dr. Jennifer Doudna (UC Berkeley): PMWC 2017 Luminary Award, January 22, 2017 @PMWC 2017, January 23-25, Silicon Valley

Reporter: Aviva Lev-Ari, PhD, RN

PMWC will be honoring Dr. Jennifer Doudna (UC Berkeley) with the Luminary Award for spearheading the development of the groundbreaking Crispr-Cas9 genome editing technology

Luminary & Pioneer Awards

The PMWC Luminary Award recognizes recent contributions of preeminent figures who have accelerated personalized medicine into the clinical marketplace. The PMWC Pioneer Award is given to rare individuals who presaged the advent of personalized medicine when less evolved technology and encouragement from peers existed, but still made major advances in the field.

This year, PMWC will be honoring Dr. Jennifer Doudna (UC Berkeley) with the Luminary Award for spearheading the development of the groundbreaking Crispr-Cas9 genome editing technology and Edward F. Chang for developing advanced neurophysiologic brain mapping methods. For the Pioneer Award, Dr. James Allison (MD Anderson Cancer Center) will be recognized for pioneering cancer immunotherapy through his discovery of the immune checkpoint blockade. Dr. Stephen Quake (Stanford) will receive a Pioneer Award for his prolific inventions of technologies in microfluidics and genetics that have enabled personalized medicine, drug discovery and non-invasive diagnostics.

When: January 22, 2017 at 6:30-8:30pm

Agenda: Award Ceremony Agenda

http://www.pmwcintl.com/2017sv/awards/

SOURCE

From: Tal Behar PMWC <talb=pmwcintl.com@mail29.atl161.mcsv.net> on behalf of Tal Behar PMWC <talb@pmwcintl.com>

Reply-To: Tal Behar PMWC <talb@pmwcintl.com>

Date: Tuesday, December 20, 2016 at 1:50 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Largest Biotech Patent Case in History Will Determine Who Owns CRISPR

Genomics Orientations for Personalized Medicine

on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

Chapter 21 in this e-Book:

Advances in Gene Editing Technology: New Gene Therapy Options in Personalized Medicine – Medical Interpretation of the Genomics Frontier – CRISPR – Cas9

Chapter Curators: Larry H Bernstein, MD, FCAP, Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

genomicsinpersonalizedmedicinecovervolumeone

Read Full Post »

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

Posted in CRISPR/Cas9 & Gene Editing, LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management on December 19, 2016| Leave a Comment »

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

Curator and Open Access Journal Editor-in-Chief: Aviva Lev-Ari, PhD, RN

2.1.5.7

2.1.5.7 We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year – Record Articles on CRISPR !!!!! Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

April 30, 2012: Launch Date for 1st Article

December 19, 2016: Date we Celebrate 5,000 Scientific Articles and 1,118,520 e-Readers

For 2016, Our Top Articles by e-Readers Views and Authors are:

These articles and others are in EIGHT e-Books on Amazon.com

Forthcoming SEVEN e-Books in 2016

https://www.linkedin.com/pulse/forthcoming-cover-pages-new-e-books-medicine-from-lev-ari-phd-rn?trk=prof-post

WE ARE ON AMAZON.COM

http://www.amazon.com/dp/B00DINFFYC

http://www.amazon.com/dp/B018Q5MCN8

http://www.amazon.com/dp/B018PNHJ84

http://www.amazon.com/dp/B018DHBUO6

http://www.amazon.com/dp/B013RVYR2K

http://www.amazon.com/dp/B012BB0ZF0

http://www.amazon.com/dp/B019UM909A

http://www.amazon.com/dp/B019VH97LU

BioMedical e-Books e-Series:

Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

https://pharmaceuticalintelligence.com/biomed-e-books/

2013 e-Book on Amazon.com

Perspectives on Nitric Oxide in Disease Mechanisms, on Amazon since 6/2/12013

http://www.amazon.com/dp/B00DINFFYC

2015 e-Book on Amazon.com

Metabolic Genomics and Pharmaceutics, on Amazon since 7/21/2015

http://www.amazon.com/dp/B012BB0ZF0

Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

Milestones in Physiology: Discoveries in Medicine, Genomics and Therapeutics, on Amazon.com since 12/27/2015

http://www.amazon.com/dp/B019VH97LU

Cardiovascular, Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation, on Amazon since 11/30/2015

http://www.amazon.com/dp/B018Q5MCN8

Cardiovascular Diseases, Volume Three: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics, on Amazon since 11/29/2015

http://www.amazon.com/dp/B018PNHJ84

Cardiovascular Diseases, Volume Four: Regenerative and Translational Medicine: The Therapeutics Promise for Cardiovascular Diseases, on Amazon since 12/26/2015

http://www.amazon.com/dp/B019UM909A

Read Full Post »

Researchers at Dana-Farber/Boston Children’s: Differences in wiring of “exhausted” and effective T cells indicate possible gene-editing targets

Posted in CRISPR/Cas9 & Gene Editing, Immuno-Oncology & Genomics, Immunotherapy on October 31, 2016| Leave a Comment »

Researchers at Dana-Farber/Boston Children’s: Differences in wiring of “exhausted” and effective T cells indicate possible gene-editing targets

Reporter: Aviva Lev-Ari, PhD, RN

“Exhausted T cells display a variety of functional defects,” says Nicholas Haining, MD, of Dana-Farber/Boston Children’s, senior author of the new paper. “They are paralyzed and don’t have the fire-power to destroy cancer or virally-infected cells. For us, the question in this study was, do exhausted cells represent a distinct type of T cell or are they merely a ‘groggy’ version of functional T cells?”

With chronically infected mice as their model, the researchers used a new technology called ATAC-seq to map the regulatory regions of the genome – the sections of DNA involved in switching genes on and off – in the animals’ exhausted and functional CD8⁺ T cells. (CD8⁺ T cells are programmed to identify and eliminate cancerous and infected cells.)

“We found the landscape of regulatory regions to be fundamentally different in exhausted and functional T cells,” Haining says. “There were thousands of instances where a regulatory region appeared in exhausted T cells but not in their functional counterparts, and vice versa. This tells us that the two types of cells use very different wiring diagrams to control their gene activity.”

The researchers then tested whether removing a regulatory stretch of DNA that spurs the production of PD-1 would drive down expression of the protein. Using CRISPR/Cas9 technology, they snipped out that region and indeed, PD-1 expression dropped.

SOURCE

http://www.danafarberbostonchildrens.org/news/research-into-basic-workings-of-immune-system-and-cancer.aspx

Read Full Post »

CRISPR Therapeutics raises a $56M IPO, but patent battles, potential stock drops loom

Posted in CRISPR/Cas9 & Gene Editing on October 19, 2016| Leave a Comment »

CRISPR Therapeutics raises a $56M IPO, but patent battles, potential stock drops loom

And then there were three: After Editas ($EDIT) and Intellia ($NTLA) went public this year, CRISPR has brought up the rear with its IPO. But the biotech will need to gear up for a tough market that has seen its rivals’ stock fall hard in the intervening months, and the ongoing patent saga on who “owns” the gene editing tech.

Switzerland and Cambridge, MA-based CRISPR Therapeutics priced its IPO at $14 a pop for 4 million shares, bringing home $56 million. This is less than the $94.4 million raised by Editas in February and the $108 million from Intellia Therapeutics in May.

Bayer, however, did buy 2.5 million shares itself at $14, bumping up another $35 million to the biotech, which will trade on the Nasdaq this week under the ticker $CRSP.

The biotech booked around $2 million in sales for the year ending June 30, 2016, although it made an operating loss of nearly $30 million in the first half of 2016.

It has already set up a JV with Bayer to create CRISPR spinoff Casebia Therapeutics as well as a collab with Vertex Pharmaceuticals ($VRTX). Bayer’s venture arm, before the offering, owned around 8% of the biotech, with Celgene ($CELG) and Glaxo’s ($GSK) venture businesses owning 12.4% and 9.7% respectively.

Caribou Biosciences, which raised $30 million in a Series B financing round back in May, remains one of the last big CRISPR biotechs to not go public.

CRISPR science has generated a lot of interest from the media over the past two years with noises increasingly linking it to potential “cures” for conditions such as sickle cell disease and a new, potentially better way of fighting certain cancers.

SOURCE

http://www.fiercebiotech.com/biotech/crispr-therapeutics-raises-a-56m-ipo-but-patent-battles-potential-stock-drops-loom?utm_medium=nl&utm_source=internal&mrkid=993697&mkt_tok=eyJpIjoiWlRsa01UY3labUl5WlRVeCIsInQiOiJWbjR3MTdTQTdCXC9yelIzSCtNMXVZdEFQZWZyelRZcFpUWmV0WlNRc2dkR2dRaFhNaTJBdlpyOUZqXC9rd1NIdm84MjhWbkZ0dnVPMDFjcjVQelZweTVVV215TUZwZ0JTZTliY1NNMWMzVEdVPSJ9

Who OWN the Patents on CRISPR-Cas9?

CRISPR patent battle heats up as new email disputes Zhang’s claims

UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The Biotech Patent Fight of the Century: UC, Berkeley and Broad Institute @MIT

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/06/status-interference-initial-memorandum-crisprcas9-the-biotech-patent-fight-of-the-century/

Read Full Post »

LIVE – Day 1, OCTOBER 18 @The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

Posted in Computational Biology/Systems and Bioinformatics, Conference Coverage with Social Media, CRISPR/Cas9 & Gene Editing, Gene Therapy & Gene Editing Development on October 18, 2016| Leave a Comment »

LIVE – Day 1, OCTOBER 18 @The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

will cover in REAL TIME

The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

http://events.technologyreview.com/emtech/16/

In attendance, streaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

@pharma_BI

@AVIVA1950

#emtechmit

2.1.5.8 LIVE – Day 1, OCTOBER 18 @The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

TUESDAY, OCTOBER 18, 2016

SOURCE

http://events.technologyreview.com/emtech/16/#section-schedule

8:00

Registration & Breakfast
9:00

Opening Remarks

Emerging technologies, including:

– Rethinking Energy

— Rewrite Biology

– Virtual Reality, Augmented Life

– Artificial intelligence

– Global Connectivity

– Engineering a Healthy Planet

– Spotlight talks on the 10 Breakthrough Technologies

– Celebration of the 2016 Innovators Under 35
9:15

Connecting for Greater Opportunity: Defining the Digital Era – from FaceBook 1.2 Billion customers around the World.

– awareness affordability and infrastructure

– 4G in US, Scandenavia, Japan, 3G in Europe, India 2G network, distribution of World population, Density of 1 sq Km, 1.6 Billion do not have mobile connections. Terragraph in Urban center to leapfrog UAVs to be used for connectivity. Terragraph Overview – ETHERNET CONNECTIVITY – GIGABIT – unlicensed 60GHz Spectrum, cloud computing, Open/R: IPv6 – Laser communication: comparable to fiber optics, 10s of Gbps per second, atmosphere absorbs and scatter: pointing and tracking system, Satellite. FACEBOOK Priorities: Density of Population, Gov’t will be favorable, population have not enough — #1 is INDIA, CHINA

9:45

Innovators Under 35 Introduction – Brian Bergstein, Editor of Technology Review
10:00

Meet Young Inventors

– Blendoor – Stephanie Lampkin

– MACH – Eshan Hoque Social Skills Trainer – My Automated Conversation Coach – ROCspeak.com

– HandTalk – Ronaldo Tenorio – Deaf People 6 million people in Brazil, barrier between Hearing and Deaf people – sign language

– Energy Systems Requires Water, Lake Mead by ~~Kelly Sanders~~ – energy vs bottle water
10:30

Break & Networking
11:00 Antolio Regalado, Editor Biotech at MIT Technology Review

Gene Therapy- A New Era of Medicine

CEO & Founder, Intellia Therapeutics, Nessan Bermingham, PhD, 2018 there will be the product in Clinics

– Gene Editing,

– CRISPR Cas9 – immune system of Bacteria, using the mechanism in Bacteria for Human cells, Cellular level

– cut DNA, coopting and shut down – cut a piece of DNA convert a mutation,

– injection of cRISPR protein – correction and the existing malformed is repaired no longer expressed

– stem cells modifies and re-injected

– KO: ATTR, AATD, HBV

– Repair: AATD, HSCs

– CAR-T cells

– genetic engineering vs gene repair

– equal access to therapy

MGH – Cellular Immunotherapy Program – Marcella Maus, PhD on T-Cell research

– blocking the checkpoints by antibo- dies, Use Tcells as drugs, scale the process, manufacturing process, recover T cell from Blood, from biopsy, who is responding and who does not respond? – Leukemia, CAR- T cells, multiple Myeloma, CURE is early to use but now it can be used COMBINATION of gen therapy follwoing gene editing and immunotherapy, CAR T- cell products for leukemia and lymphoma

Katheirne High, Spark Therapeutics
bring therapeutics to people – research to clinic
DNA defective, engineered from AAV: Vector, DNA, Target tissue to delivery
conjenetive blindness – investigational trial – get vector to retina by surgeon – clinical gain of function notices in 30 days group injected vs control group – impproved light sensitivity and mobility
first gene therapy for blindness
Himophilia – vector injected in the Liver where blood factors are produced
models of therapeuitcs: Bone marrow transplantation,
clinical cell therapy – low efficacy in adverse events – academic medical center and NIH interested vs Biotech
as Clinical Trials were successful Biotech and Pharma got interested
Access, pricing, reimbursement – How gene therapy is ONCE in a life time not an an infusion on a reccurent basis over many years – Hymophillia, no pharmacological treatment to blindness
duration of expression 5 years and counting in UK, follwoing gene therapy
premature for cure

2:00

The Robots Among Us –

Stephanie Tellex, Brown University

– 35 cm lens – Robots Distributive Lab @MIT – movie

Sangbae Kim – Robots at Work – Robotics Mobility of the Future @MIT Mechanical Engineering

– Physical interaction – BMW i3 Factory – automotive production

– Robot design paradigms: Manufacturing (lack of compliance) vs construction (lack of efficiency)

– Robot design for mobility – a robot that runs – MIT Cheeta Model

– MIT meche Biomimetic Robotics Lab – high torque, high impact mitigation

– Hermes project:

Karl Iagnemma – Intellignet Machines – nuTonomy – Singapore – Autonomous machines deliver parcels and car is never distracted – driverless car

– Robotics Lab at MIT – smart car, self driven cars, ability to learn from experience – 2017 – double fleet of drivers
12:30

Lunch & Networking

Meet Young Inventors under 35
Jagdish Chaturvedi – ENTraview – device was licensed to Medtronic and to an Indian company, developed two more product InnAccel – Bangalor — product design company
Wei Gao – Wearable Tech – Wearable Human Sweat Sensors
Imaging Technologies by Muyinatu BiSI Bell Sounds – Amplitude vs Coherence
Heather Bowerman – Hormonal Disease: Endometriosis 10% of Woman – microRNA DotLab
12:00

3:00 Meet the 2016 Innovators Under 35

Jiawei Gu Ling Robotics – Intelligent life with Robots and AI inside – Life UnpluggedInfinite of robots, Intelligence of things,

Nora Ayanian, USC – Computer vision

Maithilee Kunda, Vanderbuilt University, CS – Computer vision

Oriol V. Google, AI & Machine Learning – Deep Natural Network

Machine Translation, Text to Speech,

3:30

Break & Networking

4:00

A.I.’s Next Leap Forward – David Cox at Harvard University

networks, computations and computers as metaphor for Neuro Science and Brain Science
Brains are computational systems – Petaflops of computations
Deep learning, Artificial neuronet works – NeuroNets
Vision theory – ImageNet error rate in decrease tendency
Machine Intelligence from Cortical – DARPA
Genetics and microscopes – like wire tap in the brain
Model of Brain mapped – set hypothesis on function and anatomy

Big Data – Ruslan Salakhutdinov. Carnegie Mellon

Natural language
multimodal learning – nearest Images
unsupervised learning – no labelled data, natural Story Telling
Image understanding – deep learning
Caption generation
Semantic Relatedness: Recurrent Neural Network
One shot learning
Transfer learning
Summary: Image tagging, Category hierarchy, Speech recognition

XPrize

Google Lunar
Qualcomm Tricorder
Casio Cardon
Shell Ocean Discovery

5:00

Lemelson-MIT Prize Honors & Reception

Ramesh Raskar, Associate Professor, MIT Media Lab Camera Culture Group

Making Invisible Visible: Matter

Light to slow motion
Multi-path analysis
Published in Nature 2012
DARPA REVEAL Program 2015
Optical Brush Endoscope
Optical matter – reading in spectrum THz Imaging
wifi Camera – see through walls
EyeNetra: Eyeglasses Perscription on Phone
EyeSelfie
Camera for the Visual Challenged
Peer-to-Peer Invention – No upfront Team, Problem – Solution – REDX – sleep apnea
Blood supply Chain
Monitize garbage
Informal Sector: Street address for all – $1 wearable
The World is a Lab – REDX.io – Affordable Excellence

Lemelson Family FOundation based in Oregon is recognizing Ramesg Raskar for 2016 – MIT Prize. Inventors are recognized in the last 20 years – translation of ideas to products.

Read Full Post »

“CRISPR-Cas9, bring me a gene, Encoding for a specific protein: Three words: CRISPR. A Capella

Posted in CRISPR/Cas9 & Gene Editing on October 13, 2016| Leave a Comment »

“CRISPR-Cas9, bring me a gene, Encoding for a specific protein: Three words: CRISPR. A Capella

Reporter: Aviva Lev-Ari, PhD, RN

AROUND FLG

Hi Marc ,

A couple of serious ethical issues have arisen in the genetics news this week. First, a new study has revealed that two major clinical genomic databases show major racial bias towards European ancestry over African ancestry. Secondly, it has emerged that the ‘three-parent’ IVF technique has been used in the Ukraine to improve couples’ fertility, even though the scientific evidence to support this use is shaky at best.

And in the world of the less serious, there’s a very catchy tune doing the rounds at FLG towers. Ever since we discovered A Capella Science on YouTube, we’ve had his fantastically zany mash up of CRISPR-Cas9 and Mr Sandman going round and round in our heads. While there is obviously something delightfully zany about genome editing in close harmony, projects like this represent innovative science education at its very best.

Best wishes,

Liz Harley

Content Manager

Front Line Genomics

Three words: CRISPR. A Capella

Share this article

Three words: CRISPR. A Capella

Just trust us on this one: you need this hilariously catchy tune in your life this Monday. The latest tune from A Capella Science (who also brought us a beautiful Billy Joel-style tribute to entropic time) takes a look at everything CRISPR, from how it works to just some of the applications, all inside five perfectly harmonised minutes of glory.

“CRISPR-Cas9, bring me a gene,

Encoding for a specific protein.

Make a few snips at this coded locus.

You work so well inside a streptococcus!”

We defy you not to be humming this for the rest of your day.

More Awards to Jennifer Doudna: 2016 Warren Alpert Foundation Prize and The 2015 Pfizer Lecture

Posted in CRISPR/Cas9 & Gene Editing, Interviews with Scientific Leaders on October 9, 2016| Leave a Comment »

More Awards to Jennifer Doudna: 2016 Warren Alpert Foundation Prize and The 2015 Pfizer Lecture

Reporter: Aviva Lev-Ari, PhD, RN

WordCloud Image Produced by Adam Tubman

2.1.5.9 More Awards to Jennifer Doudna: 2016 Warren Alpert Foundation Prize and The 2015 Pfizer Lecture, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

2015 Inaugural Pfizer Lecture with Jennifer Doudna, Ph.D.

Pfizer Cambridge presents the 2015 Inaugural Pfizer Lecture honoring Jennifer Doudna, Ph.D., innovator in the field of biomedical research, on Thursday, Sept. 10, 2015

September 10, 2015 | 3:30 p.m. EST

Refreshments at 4:45 p.m.

Kresge Auditorium, MIT Campus

Free | Open to public

The 2015 Pfizer Lecture will be given by Jennifer Doudna, Ph.D., University of California, Berkeley Professor and Howard Hughes Medical Institute Investigator. Dr. Doudna is recognized for her innovative accomplishments in biomedical research, including work on the biochemical characterization of the revolutionary CRISPR-Cas9 gene editing system that is transforming biology and medicine research around the world.

The annual Pfizer Lectureship event brings together the Massachusetts life sciences community to explore noteworthy research, celebrate innovation and facilitate new connections among the broader Boston/Cambridge biomedical community. Central to the Lectureship Event is the recognition of an individual, external to Pfizer, whose scientific contributions have helped accelerate the pace of innovation.

LIVE – The CRISPR/Cas9 Revolution and Gene Editing: 2016 WARREN ALPERT FOUNDATION PRIZE SYMPOSIUM

Prize recipient:

Jennifer Doudna, PhD
Li Ka Shing Chancellor’s Chair in Biomedical and Health Sciences/HHMI Investigator
University of California, Berkeley
The Future of Genome Engineering: Biology, Technology and Ethics

LIVE – The CRISPR/Cas9 Revolution and Gene Editing: 2016 WARREN ALPERT FOUNDATION PRIZE SYMPOSIUM

Read Full Post »

FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com

Posted in CRISPR/Cas9 & Gene Editing on October 6, 2016| Leave a Comment »

FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com

Reporter: Aviva Lev-Ari, PhD, RN

2.1.5.10

2.1.5.10 Federation of European Biochemical Societies FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com – State of CRISPR/Cas9 Science on 9/2016, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

FEBS Journal Special Issue on CRISPR

FEBS Journal Special Issue on CRISPR/Cas9
The FEBS Journal

The discovery of CRISPR in archaea and bacteria
The FEBS Journal

Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens
The FEBS Journal

Next stop for the CRISPR revolution: RNA-guided epigenetic regulators
The FEBS Journal

Using CRISPR/Cas to study gene function and model disease in vivo
The FEBS Journal

Prospects and challenges of CRISPR/Cas genome editing for the study and control of neglected vector-borne nematode diseases
The FEBS Journal

Genome Engineering Tools for Building Cellular Models of Disease
The FEBS Journal

CRISPR guide RNA design for research applications
The FEBS Journal

Off-target effects of engineered nucleases
The FEBS Journal

Stacking up CRISPR against RNAi for therapeutic gene inhibition
The FEBS Journal

SOURCE

http://news.wiley.com/crispr-research-FEBS?elqTrackId=4716a6f974ef4b76985427e9452902e9&elq=00000000000000000000000000000000&elqaid=2454&elqat=2&elqCampaignId=

From: Wiley <e-service@wiley.com>

Reply-To: Wiley <e-service@wiley.com>

Date: Thursday, October 6, 2016 at 8:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: CRISPR – Read now the latest research and applications everybody is talking about

Our e-Books on Genomics include CRISPR/Cas9 Chapters, as follows:

Read Full Post »

Real Time Coverage and eProceedings of Presentations on 9/19-9/21 @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

Posted in BioTechnology - Venture Creation, BioTechnology - Venture Creation, Venture Capital, Conference Coverage with Social Media, CRISPR/Cas9 & Gene Editing, Drug Delivery Platform Technology, Drug Development Process, Drug Toxicity, FDA, Genetics & Innovations in Treatment, Genetics & Pharmaceutical, Genome Biology, Genomic Testing: Methodology for Diagnosis, Global Partnering & Biotech Investment on September 25, 2016| Leave a Comment »

Real Time Coverage and eProceedings of Presentations on 9/19-9/21 @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

Curator: Aviva Lev-Ari, PhD, RN

2.1.5.11 Real Time Coverage and eProceedings of Presentations on 9/19-9/21 @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

LIVE 9/19 8AM – 10AM USING CRISPR/Cas9 FOR FUNCTIONAL SCREENING at CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-8am-10am-using-crisprcas9-for-functional-screening-at-chis-2nd-annual-symposium-crispr-mechanisms-and-applications-chis-14th-discovery-on-target-919-9222/

LIVE 9/19 9:40 – noon CRISPR Engineering Lymphoma Lines & Will Interference from CRISPR Silence RNAi? CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-940-noon-crispr-engineering-lymphoma-lines-will-interference-from-crispr-silence-rnai-chis-2nd-annual-symposium-crispr-mechanisms-and-applications-chis-14th/

LIVE 9/19 1:40 – 3:20 EMERGING APPLICATIONS OF CRISPR/CAS9 at CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-140-320-emerging-applications-of-crisprcas9-at-chis-2nd-annual-symposium-crispr-mechanisms-and-applications-chis-14th-discovery-on-target-919-9222016/

LIVE 9/19 4PM – 5:30PM NK CELL-BASED CANCER IMMUNOTHERAPY @CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/19/live-919-4pm-530pm-nk-cell-based-cancer-immunotherapy-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/20 8AM to noon GENE THERAPIES BREAKTHROUGHS at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/20/live-920-8am-to-noon-gene-therapies-breakthroughs-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/20 2PM to 5:30PM New Viruses for Therapeutic Gene Delivery at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/20/live-920-2pm-to-530pm-new-viruses-for-therapeutic-gene-delivery-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/21 8AM to 10:55 AM Expoloring the Versatility of CRISPR/Cas9 at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-8am-to-1055-am-expoloring-the-versatility-of-crisprcas9-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/21 8AM to 2:40PM Targeting Cardio-Metabolic Diseases: A focus on Liver Fibrosis and NASH Targets at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-8am-to-240pm-targeting-cardio-metabolic-diseases-a-focus-on-liver-fibrosis-and-nash-targets-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-b/

LIVE 9/21 12:50 pm Plenary Keynote Program at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-1250-pm-plenary-keynote-program-at-chis-14th-discovery-on-target-919-9222016-westin-boston-waterfront-boston/

LIVE 9/21 3:20PM to 6:40PM KINASE INHIBITORS FOR CANCER IMMUNOTHERAPY COMBINATIONS & KINASE INHIBITORS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/09/21/live-921-320pm-to-640pm-kinase-inhibitors-for-cancer-immunotherapy-combinations-kinase-inhibitors-for-autoimmune-and-inflammatory-diseases-at-chis-14th-discovery-on-target-919/

Read Full Post »

« Newer Posts - Older Posts »

Archive for the ‘CRISPR/Cas9 & Gene Editing’ Category

Dr. Doudna: RNA synthesis capabilities of Synthego’s team represent a significant leap forward for Synthetic Biology

Synthego Raises $41 Million From Investors, Including a Top Biochemist

Other related articles published in this Open Access Online Scientific Journal include the following:

Share this:

Like this:

Dr. Jennifer Doudna (UC Berkeley): PMWC 2017 Luminary Award, January 22, 2017 @PMWC 2017, January 23-25, Silicon Valley

PMWC will be honoring Dr. Jennifer Doudna (UC Berkeley) with the Luminary Award for spearheading the development of the groundbreaking Crispr-Cas9 genome editing technology

PMWC Interview with Dr. Jennifer Doudna (UC Berkeley)

Session Themes

Event Registration

Luminary & Pioneer Awards

Other related articles published on CRISPR on this Open Access Online Scientific Journal include the following:

Genomics Orientations for Personalized Medicine

on Amazon since 11/23/2015

Chapter 21 in this e-Book:

Advances in Gene Editing Technology: New Gene Therapy Options in Personalized Medicine – Medical Interpretation of the Genomics Frontier – CRISPR – Cas9

Share this:

Like this:

We Celebrate 5,000 Scientific Articles @pharmaceuticalintelligence.com – 2016 was a GREAT Year !!!!!

April 30, 2012: Launch Date for 1st Article

December 19, 2016: Date we Celebrate 5,000 Scientific Articles and 1,118,520 e-Readers

For 2016, Our Top Articles by e-Readers Views and Authors are:

Top Posts for 365 days ending 2016-12-19 (Summarized)

These articles and others are in EIGHT e-Books on Amazon.com

Forthcoming SEVEN e-Books in 2016

WE ARE ON AMAZON.COM

BioMedical e-Books e-Series:

Cardiovascular, Genomics, Cancer, BioMed, Patient Centered Medicine

2013 e-Book on Amazon.com

2015 e-Book on Amazon.com

Share this:

Like this:

Researchers at Dana-Farber/Boston Children’s: Differences in wiring of “exhausted” and effective T cells indicate possible gene-editing targets

Share this:

Like this:

CRISPR Therapeutics raises a $56M IPO, but patent battles, potential stock drops loom

Who OWN the Patents on CRISPR-Cas9?

Share this:

Like this:

LIVE – Day 1, OCTOBER 18 @The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

will cover in REAL TIME

The 16th annual EmTech MIT – A Place of Inspiration, October 18-20, 2016, Cambridge, MA

In attendance, streaming LIVE using Social Media

TUESDAY, OCTOBER 18, 2016

Innovators Under 35 Introduction – Brian Bergstein, Editor of Technology Review

Meet Young Inventors

Gene Therapy- A New Era of Medicine

MGH – Cellular Immunotherapy Program – Marcella Maus, PhD on T-Cell research

Katheirne High, Spark Therapeutics

2:00

The Robots Among Us –

12:30

Lunch & Networking

Meet Young Inventors under 35

12:00

3:00 Meet the 2016 Innovators Under 35

Break & Networking

4:00

A.I.’s Next Leap Forward – David Cox at Harvard University

Big Data – Ruslan Salakhutdinov. Carnegie Mellon

XPrize

5:00

Lemelson-MIT Prize Honors & Reception

Lemelson Family FOundation based in Oregon is recognizing Ramesg Raskar for 2016 – MIT Prize. Inventors are recognized in the last 20 years – translation of ideas to products.

Share this:

Like this:

“CRISPR-Cas9, bring me a gene, Encoding for a specific protein: Three words: CRISPR. A Capella

Three words: CRISPR. A Capella

Three words: CRISPR. A Capella

Share this:

Like this:

More Awards to Jennifer Doudna: 2016 Warren Alpert Foundation Prize and The 2015 Pfizer Lecture

LIVE – The CRISPR/Cas9 Revolution and Gene Editing: 2016 WARREN ALPERT FOUNDATION PRIZE SYMPOSIUM

Share this:

Like this:

FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com

Share this:

Like this: